Rosemeire Yamashiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rosemeire Yamashiro has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Márcia Jorge Castejon
Instituto Adolfo Lutz
5 shared publications - Luís Fernando de Macedo Brígido
Adolfo Lutz Institute
4 shared publications - Carmem Aparecida de Freitas Oliveira
Instituto Adolfo Lutz
3 shared publications - Elaine Lopes de Oliveira
Instituto Adolfo Lutz
3 shared publications - Valéria Oliveira Silva
Virology Center Adolfo Lutz Institute São Paulo São Paulo Brazil
3 shared publications - Carlos Roberto Prudencio
Adolfo Lutz Institute
2 shared publications
Latest Publications
- Open Access
- 22 November 2024
- Published by Coordenadoria de Controle de Doencas da Secretaria de Estado da Saude de Sao Paulo in BEPA. Boletim Epidemiológico Paulista
- Vol. 21
Monitoramento da estabilidade do controle de qualidade interno para ensaios sorológicos de HIV/aids
O presente trabalho teve como objetivo avaliar a estabilidade das amostras de controle de qualidade interno (CQI), produzidas com baixo limite de reatividade (fracamente positivo), quanto à persistência da reatividade dos anticorpos anti-HIV nos soros após o armazenamento de longo prazo a -20° C. Os soros analisados – dois lotes HIV fortemente reagente (067 e 075) e dois lotes HIV fracamente reagente (CQI061 e CQI067) com diluições padronizadas para os ensaios imunoenzimático do tipo ELISA (terceira geração) e de Western blot (WB) – foram provenientes de um estudo de estabilidade realizado por Castejon et al (2014). Nesta reavaliação, após 13 anos de armazenamento, foram utilizados diferentes ensaios sorológicos disponíveis no laboratório. Os resultados revelaram a manutenção da estabilidade dos anticorpos anti-HIV; no entanto os lotes CQI061 e CQI067 apresentaram-se fortemente reagentes nos ensaios de quarta geração e houve variação da reatividade de algumas bandas no Western blot. Em função da inclusão de novas metodologias no mercado, o CQI (fracamente reagente) padronizado para um determinado teste sorológico e armazenado por longo prazo pode não executar o seu papel pretendido.
- 22 November 2024
- Published by Coordenadoria de Controle de Doencas da Secretaria de Estado da Saude de Sao Paulo in BEPA. Boletim Epidemiológico Paulista
- Vol. 21
Open AccessMonitoramento da estabilidade do controle de qualidade interno para ensaios sorológicos de HIV/aids
O presente trabalho teve como objetivo avaliar a estabilidade das amostras de controle de qualidade interno (CQI), produzidas com baixo limite de reatividade (fracamente positivo), quanto à persistência da reatividade dos anticorpos anti-HIV nos soros após o armazenamento de longo prazo a -20° C. Os soros analisados – dois lotes HIV fortemente reagente (067 e 075) e dois lotes HIV fracamente reagente (CQI061 e CQI067) com diluições padronizadas para os ensaios imunoenzimático do tipo ELISA (terceira geração) e de Western blot (WB) – foram provenientes de um estudo de estabilidade realizado por Castejon et al (2014). Nesta reavaliação, após 13 anos de armazenamento, foram utilizados diferentes ensaios sorológicos disponíveis no laboratório. Os resultados revelaram a manutenção da estabilidade dos anticorpos anti-HIV; no entanto os lotes CQI061 e CQI067 apresentaram-se fortemente reagentes nos ensaios de quarta geração e houve variação da reatividade de algumas bandas no Western blot. Em função da inclusão de novas metodologias no mercado, o CQI (fracamente reagente) padronizado para um determinado teste sorológico e armazenado por longo prazo pode não executar o seu papel pretendido.
- Open Access
- 28 August 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-12
An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines
Humoral response to SARS-CoV-2 has been studied, predominantly the classical IgG and its subclasses. Although IgE antibodies are typically specific to allergens or parasites, a few reports describe their production in response to SARS-CoV-2 and other viruses. Here, we investigated IgE specific to receptor binding domain (RBD) of SARS-CoV-2 in a Brazilian cohort following natural infection and vaccination. Samples from 59 volunteers were assessed after infection (COVID-19), primary immunization with vectored (ChAdOx1) or inactivated (CoronaVac) vaccines, and booster immunization with mRNA (BNT162b2) vaccine. Natural COVID-19 induced IgE, but vaccination increased its levels. Subjects vaccinated with two doses of ChAdOx1 exhibited a more robust response than those immunized with two doses of CoronaVac; however, after boosting with BNT162b2, all groups presented similar IgE levels. IgE showed intermediate-to-high avidity, especially after the booster vaccine. We also found IgG4 antibodies, mainly after the booster, and they moderately correlated with IgE. ELISA results were confirmed by control assays, using IgG depletion by protein G and lack of reactivity with heterologous antigen. In our cohort, no clinical data could be associated with the IgE response. We advocate for further research on IgE and its role in viral immunity, extending beyond allergies and parasitic infections.
- 28 August 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-12
Open AccessAn unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines
Humoral response to SARS-CoV-2 has been studied, predominantly the classical IgG and its subclasses. Although IgE antibodies are typically specific to allergens or parasites, a few reports describe their production in response to SARS-CoV-2 and other viruses. Here, we investigated IgE specific to receptor binding domain (RBD) of SARS-CoV-2 in a Brazilian cohort following natural infection and vaccination. Samples from 59 volunteers were assessed after infection (COVID-19), primary immunization with vectored (ChAdOx1) or inactivated (CoronaVac) vaccines, and booster immunization with mRNA (BNT162b2) vaccine. Natural COVID-19 induced IgE, but vaccination increased its levels. Subjects vaccinated with two doses of ChAdOx1 exhibited a more robust response than those immunized with two doses of CoronaVac; however, after boosting with BNT162b2, all groups presented similar IgE levels. IgE showed intermediate-to-high avidity, especially after the booster vaccine. We also found IgG4 antibodies, mainly after the booster, and they moderately correlated with IgE. ELISA results were confirmed by control assays, using IgG depletion by protein G and lack of reactivity with heterologous antigen. In our cohort, no clinical data could be associated with the IgE response. We advocate for further research on IgE and its role in viral immunity, extending beyond allergies and parasitic infections.
- Open Access
- 25 June 2024
- Published by Coordenadoria de Controle de Doencas da Secretaria de Estado da Saude de Sao Paulo in BEPA. Boletim Epidemiológico Paulista
- Vol. 21, e40444
Centro de Imunologia do Instituto Adolfo Lutz ao longo dos anos
O Instituto Adolfo Lutz (IAL) foi criado em 1940 como resultado da unificação dos Institutos Bacteriológico e Bromatológico, um moderno laboratório voltado ao controle de doenças, inaugurando uma nova fase de Laboratórios de Saúde Pública no estado de São Paulo. Os primeiros testes sorológicos oferecidos à população foram executados pelas “antigas” Seções de Sorologia e de Imunologia. Destaca-se a importância dessas seções no desenvolvimento científico do IAL pela realização de pesquisas, produção científica e inovação tecnológica, seguramente, fundamentais para a saúde pública no decorrer dos anos. O Centro de Imunologia do IAL (CIM-IAL) foi criado em 2010, com a unificação das Seções de Sorologia e Imunologia, quando ocorreu a reorganização institucional. O CIM-IAL participou de importantes avanços científicos na área da saúde, reforçando sua capacidade em desenvolver pesquisas, executar e monitorar o diagnóstico e a vigilância de diferentes agravos. Este manuscrito tem como objetivo apresentar os principais acontecimentos que ressaltam o papel fundamental na busca de soluções para os problemas de saúde pública, desde a época das Seções de Sorologia e Imunologia até tornar-se o Centro de Imunologia. Na elaboração deste trabalho foram utilizadas bibliografias contendo dados históricos, científicos e relatos de profissionais da área.
- 25 June 2024
- Published by Coordenadoria de Controle de Doencas da Secretaria de Estado da Saude de Sao Paulo in BEPA. Boletim Epidemiológico Paulista
- Vol. 21, e40444
Open AccessCentro de Imunologia do Instituto Adolfo Lutz ao longo dos anos
O Instituto Adolfo Lutz (IAL) foi criado em 1940 como resultado da unificação dos Institutos Bacteriológico e Bromatológico, um moderno laboratório voltado ao controle de doenças, inaugurando uma nova fase de Laboratórios de Saúde Pública no estado de São Paulo. Os primeiros testes sorológicos oferecidos à população foram executados pelas “antigas” Seções de Sorologia e de Imunologia. Destaca-se a importância dessas seções no desenvolvimento científico do IAL pela realização de pesquisas, produção científica e inovação tecnológica, seguramente, fundamentais para a saúde pública no decorrer dos anos. O Centro de Imunologia do IAL (CIM-IAL) foi criado em 2010, com a unificação das Seções de Sorologia e Imunologia, quando ocorreu a reorganização institucional. O CIM-IAL participou de importantes avanços científicos na área da saúde, reforçando sua capacidade em desenvolver pesquisas, executar e monitorar o diagnóstico e a vigilância de diferentes agravos. Este manuscrito tem como objetivo apresentar os principais acontecimentos que ressaltam o papel fundamental na busca de soluções para os problemas de saúde pública, desde a época das Seções de Sorologia e Imunologia até tornar-se o Centro de Imunologia. Na elaboração deste trabalho foram utilizadas bibliografias contendo dados históricos, científicos e relatos de profissionais da área.
- Open Access
- 30 May 2023
- Published by Coordenadoria de Controle de Doencas da Secretaria de Estado da Saude de Sao Paulo in BEPA. Boletim Epidemiológico Paulista
- Vol. 20, 1-20
Diagnóstico laboratorial da infecção pelo HIV em travestis e mulheres transexuais no Brasil, 2019-2021
A prevalência de HIV em travestis e mulheres transexuais (TrMT) é desproporcionalmente maior quando comparada com a população geral do Brasil. O objetivo deste estudo foi analisar – por meio de ensaios molecular e sorológicos convencionais para o diagnóstico da infecção pelo HIV – amostras de sangue de uma população TrMT de cinco capitais brasileiras que haviam apresentado resultado reagente em testes rápidos (TR). Um total de 435 amostras com resultado reagente em pelo menos um TR foi encaminhado ao laboratório de referência do estado de São Paulo – o Instituto Adolfo Lutz (IAL) –, para que elas fossem analisadas por meio de testes laboratoriais convencionais. Das amostras avaliadas, 99,3% (432/435) foram reagentes para HIV nos testes laboratoriais convencionais, sendo que, destas, 22,7% (98/432) apresentaram carga viral HIV-1 acima de 5.000 cópias/ml e 77,3% (334/432) mostraram-se reagentes em testes sorológicos (imunoensaio de quimioluminescência, ou ELISA, e imunoblot rápido). As três amostras restantes (0,7%) foram classificadas como “indeterminada para HIV”, com base em ensaios molecular e sorológicos convencionais. A sensibilidade analítica dos diferentes ensaios – molecular e sorológicos – utilizados neste estudo pode ter variado pela influência da imunossupressão viral do HIV-1 resultante da terapia antirretroviral (TARV). Estudos complementares são necessários para melhor entender o impacto da terapia no diagnóstico do HIV.
- 30 May 2023
- Published by Coordenadoria de Controle de Doencas da Secretaria de Estado da Saude de Sao Paulo in BEPA. Boletim Epidemiológico Paulista
- Vol. 20, 1-20
Open AccessDiagnóstico laboratorial da infecção pelo HIV em travestis e mulheres transexuais no Brasil, 2019-2021
A prevalência de HIV em travestis e mulheres transexuais (TrMT) é desproporcionalmente maior quando comparada com a população geral do Brasil. O objetivo deste estudo foi analisar – por meio de ensaios molecular e sorológicos convencionais para o diagnóstico da infecção pelo HIV – amostras de sangue de uma população TrMT de cinco capitais brasileiras que haviam apresentado resultado reagente em testes rápidos (TR). Um total de 435 amostras com resultado reagente em pelo menos um TR foi encaminhado ao laboratório de referência do estado de São Paulo – o Instituto Adolfo Lutz (IAL) –, para que elas fossem analisadas por meio de testes laboratoriais convencionais. Das amostras avaliadas, 99,3% (432/435) foram reagentes para HIV nos testes laboratoriais convencionais, sendo que, destas, 22,7% (98/432) apresentaram carga viral HIV-1 acima de 5.000 cópias/ml e 77,3% (334/432) mostraram-se reagentes em testes sorológicos (imunoensaio de quimioluminescência, ou ELISA, e imunoblot rápido). As três amostras restantes (0,7%) foram classificadas como “indeterminada para HIV”, com base em ensaios molecular e sorológicos convencionais. A sensibilidade analítica dos diferentes ensaios – molecular e sorológicos – utilizados neste estudo pode ter variado pela influência da imunossupressão viral do HIV-1 resultante da terapia antirretroviral (TARV). Estudos complementares são necessários para melhor entender o impacto da terapia no diagnóstico do HIV.
- Open Access
- 20 October 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (3) , 1217-1223
Inhibition of receptor‐binding domain—ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS‐CoV‐2 vaccines
Practical laboratory proxies that correlate to vaccine efficacy may facilitate trials, identify nonresponders, and inform about boosting strategies. Among clinical and laboratory markers, assays that evaluate antibodies that inhibit receptor‐binding domain (RBD) ligation to angiotensin‐converting enzyme‐2 receptor (receptor‐binding inhibition [RBI]) may provide a surrogate for viral neutralization assays. We evaluated RBI before and after a median of 34 days (interquartile range [IQR]: 33–40) of the second dose of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Sinovac's CoronaVac (CN) or AstraZeneca/Oxford's AZD1222 (AZ) vaccines in 166 individuals. Both vaccines elicited high inhibitory titers in most subjects, 95% (158/166), with signal inhibition above 30% and 89% (127/143) with more than fourfold increase from prevaccination titers, but titers tend to decrease over time. Both postvaccination inhibitory titers (95%, IQR 85%–97% for AZ vs. 79%, IQR 60%–96% for CN, p = 0.004) and pre/post‐titer increase (AZ 76%, IQR 51%–86% for AZ vs. 47%, IQR 24%–67% for CN, p < 0.0001) were higher among AZ vaccinees. Previous serological reactivity due to natural infection was associated with high prevaccination signal inhibition titers. The study documents a robust antibody response capable of interfering with RBD–angiotensin‐converting enzyme binding. Evaluation of SARS‐CoV‐2 infection incidence in these populations is necessary to assess its association to protection and its duration.
- 20 October 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (3) , 1217-1223
Open AccessInhibition of receptor‐binding domain—ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS‐CoV‐2 vaccines
Practical laboratory proxies that correlate to vaccine efficacy may facilitate trials, identify nonresponders, and inform about boosting strategies. Among clinical and laboratory markers, assays that evaluate antibodies that inhibit receptor‐binding domain (RBD) ligation to angiotensin‐converting enzyme‐2 receptor (receptor‐binding inhibition [RBI]) may provide a surrogate for viral neutralization assays. We evaluated RBI before and after a median of 34 days (interquartile range [IQR]: 33–40) of the second dose of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Sinovac's CoronaVac (CN) or AstraZeneca/Oxford's AZD1222 (AZ) vaccines in 166 individuals. Both vaccines elicited high inhibitory titers in most subjects, 95% (158/166), with signal inhibition above 30% and 89% (127/143) with more than fourfold increase from prevaccination titers, but titers tend to decrease over time. Both postvaccination inhibitory titers (95%, IQR 85%–97% for AZ vs. 79%, IQR 60%–96% for CN, p = 0.004) and pre/post‐titer increase (AZ 76%, IQR 51%–86% for AZ vs. 47%, IQR 24%–67% for CN, p < 0.0001) were higher among AZ vaccinees. Previous serological reactivity due to natural infection was associated with high prevaccination signal inhibition titers. The study documents a robust antibody response capable of interfering with RBD–angiotensin‐converting enzyme binding. Evaluation of SARS‐CoV‐2 infection incidence in these populations is necessary to assess its association to protection and its duration.
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 63
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
Twenty-seven children aged seven months to 5 years were inadvertently vaccinated with a COVID-19 vaccine, the CoronaVac (Sinovac, China), an inactivated SARS-CoV-2 vaccine, in two different cities of Sao Paulo State, Brazil. After the event, these children were monitored by local pediatricians and serum samples were collected at the first visit and 30 days after vaccination and tested for SARS-CoV-2 S1 serology with Ortho total IgG anti-S1 protein and Cpass, an ACE2 receptor binding domain inhibition assay. Only one child had a mild symptom after vaccination, with no other adverse events documented up to the 30 days follow-up. Of 27 children tested 3-9 days after vaccination, 5 (19%) had positive serology suggesting a previous natural SARS-CoV-2 infection, with all 19 tested on day 30 after vaccination and presenting with positive tests, with an increment of antibody titers in those initially positive. A low Cpass binding inhibition was observed in the first collection in 11 seronegative cases, with high titers among those anti-S1 positive. All children showed an important increase in antibody titers on day 30. The event allowed the documentation of a robust serological response to one dose of CoronaVac in this small population of young children, with no major adverse effects. Although it was an unfortunate accident, this event may contribute with future vaccine strategies in this age group. The data suggest that CoronaVac is safe and immunogenic for children.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 63
Open AccessSafety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
Twenty-seven children aged seven months to 5 years were inadvertently vaccinated with a COVID-19 vaccine, the CoronaVac (Sinovac, China), an inactivated SARS-CoV-2 vaccine, in two different cities of Sao Paulo State, Brazil. After the event, these children were monitored by local pediatricians and serum samples were collected at the first visit and 30 days after vaccination and tested for SARS-CoV-2 S1 serology with Ortho total IgG anti-S1 protein and Cpass, an ACE2 receptor binding domain inhibition assay. Only one child had a mild symptom after vaccination, with no other adverse events documented up to the 30 days follow-up. Of 27 children tested 3-9 days after vaccination, 5 (19%) had positive serology suggesting a previous natural SARS-CoV-2 infection, with all 19 tested on day 30 after vaccination and presenting with positive tests, with an increment of antibody titers in those initially positive. A low Cpass binding inhibition was observed in the first collection in 11 seronegative cases, with high titers among those anti-S1 positive. All children showed an important increase in antibody titers on day 30. The event allowed the documentation of a robust serological response to one dose of CoronaVac in this small population of young children, with no major adverse effects. Although it was an unfortunate accident, this event may contribute with future vaccine strategies in this age group. The data suggest that CoronaVac is safe and immunogenic for children.
- Open Access
- 1 January 2020
- Published by GN1 Sistemas e Publicacoes Ltd. in Jornal Brasileiro de Patologia e Medicina Laboratorial
Performance evaluation of HIV infection diagnostic tests
- 1 January 2020
- Published by GN1 Sistemas e Publicacoes Ltd. in Jornal Brasileiro de Patologia e Medicina Laboratorial
Open AccessPerformance evaluation of HIV infection diagnostic tests
- Open Access
- 1 January 2014
- Published by GN1 Sistemas e Publicacoes Ltd. in Jornal Brasileiro de Patologia e Medicina Laboratorial
- Vol. 50 (4)
Stability of anti-HIV antibodies in serum samples stored for two to eighteen years periods
Introduction: The antibodies have an important role in the serodiagnosis, constituting the most widely used biomarkers to detect and confirm various diseases. Objective: To investigate the reproducibility of anti-human immunodeficiency virus (HIV) antibodies reactivity, to assess the stability of the sera samples stored at -20ºC for two to eighteen years. Method: Sera were collected in the period 1988-2004 for routine anti-HIV antibodies diagnostic testing. The remaining samples stored at -20ºC, were analyzed in this study. Serum sample stability was assessed by enzyme-linked immunosorbent assay/enzyme immunoassay (ELISA/EIA), indirect immunofluorescence assay (IFA), and Western blot (WB) for detecting anti-HIV antibodies. The previously found results (1988-2004) and those obtained in 2006 were subjected to Kappa index analysis. Result: In the period 1988-to 2004, the degree of concordance of the ELISA/EIA, IFA and WB results were considered, good (k = 0.80), regular (k = 0.35), and good (k = 0.63), respectively. Conclusion: Regarding HIV serologic test, the serum samples were stable for 18 years in ELISA/EIA and for 4 years in IFA technique, however, for the WB methodology it was not possible to determine the time of stability of the anti-HIV antibodies
- 1 January 2014
- Published by GN1 Sistemas e Publicacoes Ltd. in Jornal Brasileiro de Patologia e Medicina Laboratorial
- Vol. 50 (4)
Open AccessStability of anti-HIV antibodies in serum samples stored for two to eighteen years periods
Introduction: The antibodies have an important role in the serodiagnosis, constituting the most widely used biomarkers to detect and confirm various diseases. Objective: To investigate the reproducibility of anti-human immunodeficiency virus (HIV) antibodies reactivity, to assess the stability of the sera samples stored at -20ºC for two to eighteen years. Method: Sera were collected in the period 1988-2004 for routine anti-HIV antibodies diagnostic testing. The remaining samples stored at -20ºC, were analyzed in this study. Serum sample stability was assessed by enzyme-linked immunosorbent assay/enzyme immunoassay (ELISA/EIA), indirect immunofluorescence assay (IFA), and Western blot (WB) for detecting anti-HIV antibodies. The previously found results (1988-2004) and those obtained in 2006 were subjected to Kappa index analysis. Result: In the period 1988-to 2004, the degree of concordance of the ELISA/EIA, IFA and WB results were considered, good (k = 0.80), regular (k = 0.35), and good (k = 0.63), respectively. Conclusion: Regarding HIV serologic test, the serum samples were stable for 18 years in ELISA/EIA and for 4 years in IFA technique, however, for the WB methodology it was not possible to determine the time of stability of the anti-HIV antibodies